The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.
Briceno, D., Mohanty, P., Di Biase, L., Romero, J., Della Rocca, D., Trivedi, C., et al. (2020). CABANA trial: "beauty is in the eye of the beholder". JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 57(1), 1-3 [10.1007/s10840-019-00604-0].
CABANA trial: "beauty is in the eye of the beholder"
Natale A
2020-01-01
Abstract
The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.| File | Dimensione | Formato | |
|---|---|---|---|
|
Natale2020.1.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
171.96 kB
Formato
Adobe PDF
|
171.96 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
